Flagship's Kintai debuts with small molecule microbiome mimic platform, CEO Tak

Kintai Therapeutics Inc. (Cambridge, Mass.) emerged from stealth mode Tuesday, defining Flagship Pioneering's fourth angle on microbiome-based therapeutics. The biotech's orally bioavailable small molecules mimic interactions between the microbiome and host cells to drive therapeutic effects in a range of target tissues, including the liver and brain (see “Kintai’s Host-Targeting Niche in Flagship Microbiome Ecosystem”).

CEO Paul-Peter Tak joined Flagship as a venture partner in January after stepping down as SVP of R&D, chief immunology officer and development lead at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...